E-LIB Suche - Ergebnisse für: Eichhorst, Barbara F. - Sprache EN

Search for persons X

Sorted by: Relevance

Sorted by: Year

1

Enduring undetectable MRD and updated outcomes in relapsed/..:

Seymour, John F. ; Kipps, Thomas J. ; Eichhorst, Barbara F....
Blood. 140 (2022) 8 - p. 839-850 , 2022

Link: https://doi.org/10.1182/..

2

Sequential treatment with bendamustine, obinutuzumab (GA101..:

von Tresckow, Julia ; Cramer, Paula ; Robrecht, Sandra...
Leukemia. 36 (2022) 8 - p. 2125-2128 , 2022

Link: https://doi.org/10.1038/..

3

Efficacy and Safety of the Combination of Tirabrutinib and ..:

Kutsch, Nadine ; Pallasch, Christian ; Tausch, Eugen...
HemaSphere. 6 (2022) 4 - p. e692 , 2022

Link: https://doi.org/10.1097/..

4

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractor..:

Hillmen, Peter ; Brown, Jennifer R ; Eichhorst, Barbara F...
Future Oncology. 16 (2020) 10 - p. 517-523 , 2020

Link: https://doi.org/10.2217/..

5

CLL2-BIG: sequential treatment with bendamustine, ibrutinib..:

von Tresckow, Julia ; Cramer, Paula ; Bahlo, Jasmin...
Leukemia. 33 (2018) 5 - p. 1161-1172 , 2018

Link: https://doi.org/10.1038/..

6

Alemtuzumab consolidation in chronic lymphocytic leukaemia:..:

Al‐Sawaf, Othman ; Fischer, Kirsten ; Herling, Carmen D....
European Journal of Haematology. 98 (2016) 3 - p. 254-262 , 2016

Link: https://doi.org/10.1111/..

7

Consolidation with alemtuzumab improves progression‐free su..:

Schweighofer, Carmen D. ; Ritgen, Matthias ; Eichhorst, Barbara F....
British Journal of Haematology. 144 (2008) 1 - p. 95-98 , 2008

Link: https://doi.org/10.1111/..

8

Use of alemtuzumab and rituximab consolidation in CLL: Pros..:

Elter, Thomas ; Eichhorst, Barbara F. ; Wendtner, Clemens-Martin
Current Hematologic Malignancy Reports. 4 (2008) 1 - p. 43-46 , 2008

Link: https://doi.org/10.1007/..

9

Due to low infection rates no routine anti‐infective prophy..:

Eichhorst, Barbara F. ; Busch, Raymonde ; Schweighofer, Carmen...
British Journal of Haematology. 136 (2006) 1 - p. 63-72 , 2006

Link: https://doi.org/10.1111/..

10

Enduring undetectable MRD and updated outcomes in relapsed/..:

Seymour, John F ; Kipps, Thomas J ; Eichhorst, Barbara F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412011/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Sequential treatment with bendamustine, obinutuzumab (GA101..:

von Tresckow, Julia ; Cramer, Paula ; Robrecht, Sandra...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343250/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Efficacy and Safety of the Combination of Tirabrutinib and ..:

Kutsch, Nadine ; Pallasch, Christian ; Tausch, Eugen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906452/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Six-year follow-up and subgroup analyses of a phase 2 trial..:

Stilgenbauer, Stephan ; Tausch, Eugen ; Roberts, Andrew W....
Blood Advances. 8 (2024) 8 - p. 1992-2004 , 2024

Link: https://doi.org/10.1182/..

14

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALY..:

Kater, Arnon ; Harrup, Rosemary ; Kipps, Thomas J...
HemaSphere. 7 (2023) S3 - p. e492813f , 2023

Link: https://doi.org/10.1097/..

15

CLL-092: Phase 3 Trial of Acalabrutinib in Combination with..:

Brown, Jennifer R. ; Eichhorst, Barbara ; Ghia, Paolo...
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S221-S222 , 2020

Link: https://doi.org/10.1016/..

1-15